Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$2.60 USD
-0.04 (-1.52%)
Updated Apr 22, 2024 11:55 AM ET
After-Market: $2.59 -0.01 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
HRTX 2.60 -0.04(-1.52%)
Will HRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HRTX
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
Other News for HRTX
Heron Therapeutics management to meet virtually with Northland
Heron Therapeutics management to meet virtually with Northland
Heron Therapeutics management to meet virtually with Northland
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Commit To Purchase Heron Therapeutics At $2, Earn 17% Annualized Using Options